Serenoa repens (Permixon®): A 5α-reductase types I and II inhibitor - New evidence in a coculture model of BPH

Prostate

Volumn 40, Issue 4, 1999, Pages 232-241

  Bayne, Colin W ^a   Donnelly, Frank ^a   Ross, Margaret ^a   Habib, Fouad K ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 reductase type I; 5 reductase type II; BPH; Coculture; Permixon ; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ARTICLE; COCULTURE; CONTROLLED STUDY; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MODEL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SABAL;

ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; CELL DIVISION; COCULTURE TECHNIQUES; EPITHELIAL CELLS; FIBROBLASTS; FORMAZANS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MICROSCOPY, ELECTRON; PLANT EXTRACTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SERENOA; STROMAL CELLS; TESTOSTERONE 5-ALPHA-REDUCTASE; TETRAZOLIUM SALTS;

EID: 0032811371     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0     Document Type: Article

References (44)

1. Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo controlled study. J Urol 1975;114:564-568.
2. Stone N, Ray PS, Smith JA. A double-blind radiological controlled study of the effect of flutamide on benign hypertrophy - clinical efficacy. J Urol 1989;141:240.
3. Bosch RJ, Griffiths DJ, Blom J, Schroeder FH. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 1989;141:68-72.
4. Winter ML, Bosland MC, Wade DR, Falvo RE, Nagamani M, Liehr JGP. Induction of benign prostatic hyperplasia in intact dogs by near physiological levels of 5 alpha-dihydrotestosterone and 17 beta-estradiol. Prostate 1995;26:325-333.
5. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405-409.
6. Imperato-McGinley J, Guevro L, Gauteri T, Petersen RE. Steroid 5-alpha-reductase deficiency in a man: an inherited form of pseudohermaphroditism. Science 1974;186:1213-1215.
7. Farnsworth WE, Slaunwhite WR, Sharman M, Oseko F, Brown JR, Gonder MJ, Cartagena R. Interaction of prolactin and testosterone in human prostate. Urol Res 1981;9:79-88.
8. Habib FK, Ross M, Bayne CW, Grigor K, Buck AC, Chapman K. The localization and expression of 5α-reductase type I and type II mRNA in human hyperplastic prostate and in primary cultures. J Endocrinol 1998;156:509-517.
9. Stoner E. The clinical development of 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37:375-378.
10. Delos S, Iehlé C, Martin PM, Raynaud JP. Inhibition of the activity of "basic" α-reductase (type I) detected in DU145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994;48: 347-352.
11. Buck AC. Phytotherapy for the prostate. Br J Urol 1996;78:325-336.
12. Iehlé C, Délos S, Guirou O, Tate R, Raynaud J-P, Martin P-M. Human prostatic steroid 5α-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995; 54:273-279.
13. Tarayre, JP, Delhon A, Lauressergues H, Stenger A, Barbara M, Bru M, Villanova G, Caillol V. Anti-edematous activity of the stone fruit of Serenoa repens Bartr. Ann Pharm Fr 1983;41:559-570.
14. 2 activity and on arachidonic acid metabolism in cultured prostatic cells. In: Di Silverio F, Steg A, editors. New trends in BPH etiopathogenesis. Rome: Acta Medica; 1988. p 293-296.
15. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83.
16. 4) from human polymorphonuclear neutrophils. Prostaglandins Leukotrienes Essent Fatty Acids 1997;57: 299-304.
17. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta J-M, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33:340-345.
18. Ravenna L, Di Silverio F, Russo M, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E. Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate 1996;29:219-230.
19. Vacher P, Prevarskaya N, Skryma R, Audy MC, Vacher AM, Odessa MF, Dufy B. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995;2:357-365.
20. Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem 1984;20:515-519.
21. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B. Comparison of finasteride (Proscar®), a 5α-reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α-reductase inhibition. Prostate 1993;22: 43-51.
22. Bayne CW, Donnelly F, Chapman K, Bollina P, Buck AC, Habib FK. A novel co-culture model for benign prostatic hyperplasia expressing both isoforms of 5α-reductase. J Clin Endocrinol Metab 1998;83:206-213.
23. Tsugaya M, Habib FK, Chisholm GD, Ross M, Tozawa K, Hayashi Y, Kohri K, Tanaka S. Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res 1996;24:265-271.
24. Habib FK. Regulation of prostate growth in culture with the pollen extract, cernitin T-60 and the impact of the drug on the EGF tissue profiles. In: Vahlensick W, Rutishuaser G, editors. Benign prostate diseases. Stuttgart and New York: Thieme Verlag; 1992. p 120-128.
25. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987;47:943-946.
26. Smith CM, Ballard SA, Worman N, Buettner R, Master J. 5α-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996;81: 1361-1366.
27. Houston B, Chisholm GD, Habib FK. Solubilization of human prostatic 5α-reductase. J Steroid Biochem 1985;22:461-467.
28. Svitkina TM, Veskhorsky AB, Bonisy GG. Improved procedures for electron microscopic visualisation of the cytoskeleton of cultured cells. J Struct Biol 1995;115:290-303.
29. Carraro J-C, Raynaud JJ, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-240.
30. Pisani E. National experience on therapeutic use of Serenoa repens. New Trends Androl Sci 1985;1:110-112.
31. Reece-Smith H, Memon A, Smart CJ, Dewbury K. The value of Permixon® in benign prostatic hypertrophy. Br J Urol 1986;58: 36-40.
32. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;5:291-297.
33. Fitzpatrick JM, Lynch TH. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995;22:407-412.
34. Iehlé C, Délos S, Martin P-M, Raynaud J-P. Comparative inhibition of type 1 and type 2 5 alpha-reductase activity by the n-hexane lipid/sterol extract of Serenoa repens (Permixon®) and by finasteride. In: Dimopoulos CA, Di Silverio F, editors. Bologna: Monduzzi Editore; 1996. p 22-33.
35. Briley M, Carilla E, Fauran F. Permixon®, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in rat prostate. Br J Pharmacol 1983;79:327-336.
36. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-5386.
37. Grant ES, Batchelor KW, Habib FK. Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate 1996;29:339-349.
38. Mickey DD, Stone KR, Wunderli H, Mickey GH, Paulson DF. Characterisation of a human prostate adenocarcinoma cell line (DU145) as a monolayer culture and as a solid tumour in athymic mice. Prog Clin Biol Res 1980;37:67-84.
39. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterisation of a human prostate carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
40. Kaighn ME, Lechner JF, Babcock MS, Marnell M, Ohnuki Y, Narayan KS. The Pasadena cell lines. Prog Clin Biol Res 1980; 37:85-109.
41. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57:714-719.
42. + 4-ene-oxide-reductase; EC1.3.1.22) in a stable and active form. J Steroid Biochem Mol Biol 1991;38:73-77.
43. Savory JGA, May D, Reich T, La Casse EC, Lakins J, Tenniswood M, Raymond Y, Hache RJG, Sikorska M, Lefebvre YA. 5α-reductase type I is localised to the outer nuclear membrane. Mol Cell Endocrinol 1995;110:137-147.
44. Di Silverio F, D'Eramo G, Lubrako C, Flummia GP, Sciarra A, Palma E, Caponero M, Sciarra F. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign hypertrophy patient. Eur Urol 1992;21:309-314.